Arcutis Biotherapeutics Inc (ARQT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.57B
Last updated: Nov 17, 2026 at 11:04 AM ET
Arcutis Biotherapeutics Inc (ARQT) Financials: Revenue, Profit and Cash Flow
Arcutis Biotherapeutics reported revenue of $376.07M for the fiscal year ended Dec 31, 2025, up 91.3% from the year before. That year, net income was -$16.14M with a net margin of -4.3%, operating cash flow was -$5.63M and free cash flow was -$6.31M. The quarter ended Sep 30, 2026 had revenue of $143.92M and net income of $8.80M.
Revenue and Margins
The operating margin was -3.3% in the fiscal year ended Dec 2025.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $376.07M | +91.3% | 90.2% | -3.3% | -4.3% |
| Dec 2024 | $196.54M | +229.7% | 90.3% | -65.3% | -71.3% |
| Dec 2023 | $59.61M | +1517.1% | 91.6% | -404.5% | -439.8% |
| Dec 2022 | $3.69M | N/A | 79.5% | -8183.0% | -8449.8% |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income rose 18.8% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $376.07M | $196.54M | $59.61M | $3.69M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $36.70M | $19.13M | $4.99M | $754.00K | $0 | $0 | $0 | $0 | N/A |
| Gross profit | $339.38M | $177.41M | $54.62M | $2.93M | $0 | $0 | $0 | $0 | N/A |
| Research and development | $77.05M | $76.42M | $110.58M | $182.44M | $145.56M | $115.31M | $36.52M | $17.94M | $3.41M |
| Operating income | -$12.23M | -$128.40M | -$241.10M | -$301.63M | -$206.53M | -$136.65M | -$43.13M | -$19.73M | -$4.11M |
| Net income | -$16.14M | -$140.04M | -$262.14M | -$311.46M | -$206.36M | -$135.68M | -$42.00M | -$19.25M | -$4.98M |
| EBITDA | -$9.21M | N/A | N/A | -$297.13M | -$202.45M | -$135.48M | -$42.28M | -$19.27M | -$4.11M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $143.92M | $129.86M | $105.40M | $129.50M | $99.22M | $81.50M | $65.85M | $71.36M | $44.76M | $30.86M | $49.57M | $13.53M |
| Gross profit | $131.46M | $118.92M | $95.61M | $117.81M | $90.53M | $74.01M | $57.02M | $64.45M | $39.25M | $27.39M | $46.31M | $11.28M |
| Operating income | $9.44M | $16.43M | -$9.09M | $18.39M | $8.53M | -$14.61M | -$24.53M | -$7.63M | -$39.07M | -$50.08M | -$31.62M | -$61.17M |
| Net income | $8.80M | $15.01M | -$11.29M | $17.39M | $7.41M | -$15.89M | -$25.06M | -$10.79M | -$41.54M | -$52.33M | -$35.38M | -$66.28M |
Balance Sheet
As of Dec 2025, total debt of $108.96M exceeded cash and equivalents by $66.05M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $432.97M | $348.89M | $341.37M | $449.27M | $408.15M | $298.27M | $107.01M | $51.10M | $3.82M |
| Current assets | $411.23M | $335.82M | $330.43M | $437.41M | $402.77M | $292.83M | $106.47M | $51.10M | $3.82M |
| Cash and equivalents | $42.91M | $71.33M | $88.40M | $53.64M | $96.45M | $65.08M | $63.34M | $39.39M | $3.42M |
| Total liabilities | $243.49M | $191.35M | $252.70M | $239.69M | $110.47M | $27.65M | $5.55M | $75.08M | $8.81M |
| Short-term debt | $1.00M | $0 | $735.00K | $1.31M | $433.00K | N/A | $178.00K | N/A | N/A |
| Long-term debt | $107.96M | $107.20M | $201.80M | $197.77M | $72.35M | N/A | N/A | N/A | $966.00K |
| Shareholder equity | $189.48M | $157.54M | $88.67M | $209.58M | $297.68M | $270.62M | -$65.03M | -$23.99M | -$4.99M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $524.43M | $488.54M | $460.00M | $432.97M | $370.98M | $352.43M | $344.11M | $348.89M | $437.35M | $444.76M | $478.54M | $341.37M |
| Total liabilities | $280.46M | $267.96M | $270.36M | $243.49M | $212.90M | $213.46M | $201.45M | $191.35M | $280.71M | $258.33M | $253.60M | $252.70M |
| Cash and equivalents | $33.37M | $34.12M | $34.76M | $42.91M | $47.12M | $72.74M | $53.10M | $71.33M | $134.85M | $84.27M | $190.10M | $88.40M |
| Shareholder equity | $243.97M | $220.58M | $189.65M | $189.48M | $158.07M | $138.97M | $142.66M | $157.54M | $156.64M | $186.43M | $224.94M | $88.67M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.63M | -$112.16M | -$247.06M | -$257.71M | -$174.63M | -$113.03M | -$42.84M | -$14.09M | -$3.77M |
| Capital expenditures | $686.00K | $143.00K | $428.00K | $333.00K | $995.00K | $321.00K | $295.00K | $0 | $295.00K |
| Free cash flow | -$6.31M | -$112.30M | -$247.49M | -$258.05M | -$175.62M | -$113.35M | -$43.13M | -$14.09M | -$4.07M |
| Dividends paid | N/A | N/A | N/A | $122.81M | $72.35M | N/A | N/A | N/A | N/A |
| Investing cash flow | -$30.25M | $28.82M | $180.23M | -$87.20M | -$75.95M | -$181.82M | -$26.32M | -$11.53M | -$11.53M |
| Financing cash flow | $6.97M | $66.20M | $101.32M | $301.80M | $281.95M | $298.14M | $93.10M | $61.59M | $7.12M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $18.90M | $12.64M | $2.24M | $26.18M | -$1.75M | $324.00K | -$30.38M | -$748.00K | -$34.69M | -$45.12M | -$31.60M | -$56.24M |
| Capital expenditures | $97.00K | $158.00K | $0 | $0 | $0 | $78.00K | $608.00K | $5.00M | $143.00K | $0 | $0 | $6.00K |
| Free cash flow | $18.80M | $12.48M | $2.24M | $26.18M | -$1.75M | $246.00K | -$30.99M | -$5.75M | -$34.83M | -$45.12M | -$31.60M | -$56.25M |
Frequently Asked Questions About ARQT
What is Arcutis Biotherapeutics' annual revenue?
Arcutis Biotherapeutics reported revenue of $376.07M for the fiscal year ended Dec 31, 2025.
How fast is Arcutis Biotherapeutics' revenue growing?
Revenue was up 91.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 367.3%.
Is Arcutis Biotherapeutics profitable?
No. Arcutis Biotherapeutics reported net income of -$16.14M for the fiscal year ended Dec 31, 2025, with a net margin of -4.3%.
How much free cash flow does ARQT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$5.63M minus capital expenditures of $686.00K produced free cash flow of -$6.31M.
How much debt does Arcutis Biotherapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $107.96M, short-term debt of $1.00M and cash and equivalents of $42.91M.
ARQT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors